


CLAIMS

1. A modified release pharmaceutical composition comprising, as active ingredient, a compound of formula (I):



5 wherein

R^1 represents C_{1-2} alkyl substituted by one or more fluoro substituents;

R^2 represents hydrogen, hydroxy, methoxy or ethoxy; and

n represents 0, 1 or 2;

or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or

10 carrier; provided that the formulation may only contain iota-carrageenan and a neutral gelling polymer when the compound of formula (I) is in the form of a salt.

2. A composition as claimed in claim 1 wherein the active ingredient is a salt of:

$\text{Ph}(3\text{-Cl})(5\text{-OCHF}_2)\text{-(R)CH(OH)C(O)-(S)Aze-Pab(OMe)}$;

15 $\text{Ph}(3\text{-Cl})(5\text{-OCHF}_2)\text{-(R)CH(OH)C(O)-(S)Aze-Pab}(2,6\text{-diF})(\text{OMe})$; or

$\text{Ph}(3\text{-Cl})(5\text{-OCH}_2\text{CH}_2\text{F})\text{-(R)CH(OH)C(O)-(S)Aze-Pab(OMe)}$.

3 A composition as claimed in claim 1 or 2 wherein the active ingredient is a crystalline salt of:

20 $\text{Ph}(3\text{-Cl})(5\text{-OCHF}_2)\text{-(R)CH(OH)C(O)-(S)Aze-Pab(OMe)}$;

$\text{Ph}(3\text{-Cl})(5\text{-OCHF}_2)\text{-(R)CH(OH)C(O)-(S)Aze-Pab}(2,6\text{-diF})(\text{OMe})$; or

$\text{Ph}(3\text{-Cl})(5\text{-OCH}_2\text{CH}_2\text{F})\text{-(R)CH(OH)C(O)-(S)Aze-Pab(OMe)}$.

4. A composition as claimed in any one of claims 1, 2 or 3 wherein the active

25 ingredient is an ethanesulfonic acid, *n*-propanesulfonic acid, benzenesulfonic acid,

1,5-naphthalenedisulfonic acid, or n-butanesulfonic acid addition salt of Ph(3-Cl)(5-OCHF₂)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe) or Ph(3-Cl)(5-OCHF₂)-(R)CH(OH)C(O)-(S)Aze-Pab(2,6-diF)(OMe).

- 5 5. A composition as claimed in any one of claims 1 to 4 wherein the active ingredient is Ph(3-Cl)(5-OCHF₂)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe), benzene-sulfonic acid salt, characterised by an X-ray powder diffraction pattern characterised by peaks with d-values at 5.9, 4.73, 4.09 and 4.08 Å.
- 10 6. A composition as claimed in any one of claims 1 to 4 wherein the active ingredient is Ph(3-Cl)(5-OCHF₂)-(R)CH(OH)C(O)-(S)Aze-Pab(2,6-diF)(OMe), hemi-1,5-naphthalenedisulfonic acid salt, characterised by an X-ray powder diffraction pattern characterised by peaks with d-values at 18.3, 9.1, 5.6, 5.5, 4.13, 4.02, 3.86, 3.69 and 3.63 Å.
- 15 7. A composition as claimed in any one of claims 1 to 6 wherein the composition comprises a gelling matrix.
8. A composition as claimed in claim 7 wherein the matrix comprises HPMC.
- 20 9. A composition as claimed in claim 7 or 8 wherein the matrix comprises iota-carrageenan.
10. A composition as claimed in claim 7 wherein the matrix comprises SDS.
- 25 11. The use of a formulation as claimed in claim 1 as a medicament.
12. The use of a formulation as claimed in claim 1 in the manufacture of a medicament for the treatment of a cardiovascular disorder.

13. A method of treating a cardiovascular disorder in a patient suffering from, or at risk of, said disorder, which comprises administering to the patient a therapeutically effective amount of a pharmaceutical formulation as claimed in claim 1.